See more : Sintex Industries Limited (SINTEX.NS) Income Statement Analysis – Financial Results
Complete financial analysis of GeneReach Biotechnology Corp. (4171.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GeneReach Biotechnology Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Boliden AB (publ) (BOLIF) Income Statement Analysis – Financial Results
- KDDI Corporation (KDDIY) Income Statement Analysis – Financial Results
- ThreeD Capital Inc. (IDK.CN) Income Statement Analysis – Financial Results
- ArcPacific Resources Corp. (ACP.V) Income Statement Analysis – Financial Results
- Valencia Capital Inc. (VAL-P.V) Income Statement Analysis – Financial Results
GeneReach Biotechnology Corp. (4171.TWO)
About GeneReach Biotechnology Corp.
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers automatic nucleic acid extraction systems, prep homogenization system, and mini centrifuge equipment; and reagents and consumables, comprising human IVD assays, iiPCR specific reagents, taco nucleic acid extraction reagents, IQ real quantitative systems, IQ2000 detection and prevention systems, and research reagents and consumables. The company also provides polymerase chain reaction training programs, molecular diagnostic technical solutions, laboratory installation services, OEM/ODM contract manufacturing services, and research collaboration services. It serves aquaculture, agriculture, food, and human health industries, as well as companion animals and livestock. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 225.46M | 750.02M | 1.01B | 857.03M | 365.80M |
| Cost of Revenue | 197.88M | 259.95M | 265.10M | 221.59M | 63.75M |
| Gross Profit | 27.58M | 490.07M | 746.98M | 635.45M | 302.04M |
| Gross Profit Ratio | 12.23% | 65.34% | 73.81% | 74.14% | 82.57% |
| Research & Development | 61.46M | 58.81M | 56.61M | 68.78M | 40.96M |
| General & Administrative | 121.33M | 135.85M | 146.90M | 135.12M | 96.67M |
| Selling & Marketing | 52.65M | 55.20M | 56.06M | 74.14M | 50.47M |
| SG&A | 173.98M | 191.05M | 202.96M | 209.27M | 149.15M |
| Other Expenses | 0.00 | 35.36M | -7.11M | -12.98M | 0.00 |
| Operating Expenses | 256.87M | 249.86M | 259.57M | 278.05M | 190.10M |
| Cost & Expenses | 454.75M | 509.81M | 524.67M | 499.64M | 253.85M |
| Interest Income | 14.47M | 2.29M | 392.00K | 376.00K | 777.00K |
| Interest Expense | 5.76M | 6.61M | 6.26M | 3.82M | 4.14M |
| Depreciation & Amortization | 68.89M | 65.17M | 60.01M | 51.84M | 21.04M |
| EBITDA | -143.70M | 343.02M | 540.70M | 396.59M | 132.98M |
| EBITDA Ratio | -63.73% | 45.73% | 53.42% | 46.27% | 36.35% |
| Operating Income | -229.29M | 277.85M | 480.69M | 344.75M | 111.94M |
| Operating Income Ratio | -101.70% | 37.05% | 47.50% | 40.23% | 30.60% |
| Total Other Income/Expenses | 10.94M | -5.48M | -18.04M | -18.45M | -6.45M |
| Income Before Tax | -218.35M | 272.37M | 469.37M | 338.94M | 105.49M |
| Income Before Tax Ratio | -96.84% | 36.32% | 46.38% | 39.55% | 28.84% |
| Income Tax Expense | -47.99M | 54.88M | 98.90M | 75.21M | 11.84M |
| Net Income | -166.27M | 221.34M | 376.62M | 257.28M | 77.18M |
| Net Income Ratio | -73.75% | 29.51% | 37.21% | 30.02% | 21.10% |
| EPS | -2.89 | 3.85 | 6.55 | 4.48 | 1.41 |
| EPS Diluted | -2.89 | 3.77 | 6.45 | 4.47 | 1.37 |
| Weighted Avg Shares Out | 57.46M | 57.46M | 57.46M | 57.46M | 56.25M |
| Weighted Avg Shares Out (Dil) | 57.46M | 59.29M | 58.63M | 57.55M | 57.46M |
Source: https://incomestatements.info
Category: Stock Reports